12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

CBio, Novo Nordisk deal

CBio said Novo Nordisk will not exercise its option under a May 2008 deal to negotiate an exclusive license to CBio's autoimmune product XToll...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >